AN2 Therapeutics, Inc., a Menlo Park, Calif.-based biopharmaceutical company focused on the research, development, and commercialization of novel medicines targeting infectious diseases, raised $12m in Series A financing.
The round was led by Mountain Group Partners and joined by Adjuvant Capital, Brii Biosciences, and BioRock Ventures.
The company intends to use the funds to advance its lead clinical-stage program, involving a therapeutic agent with a novel mechanism-of-action, as well as several earlier stage programs.
Led by Eric Easom, co-founder and CEO, AN2 Therapeutics is a global health biopharmaceutical company focused on bringing modern biomedical and drug development expertise to create transformational medicines for patients suffering from infectious diseases.
AN2 also announced a strategic partnership with Brii Biosciences, a clinical-stage company committed to serving patients’ needs and improving public health in China and around the world. Under the terms of the agreement, Brii Biosciences will obtain a license to develop, manufacture, and commercialize AN2’s lead clinical-stage antibacterial compound with a novel mechanism-of-action in greater China.
FinSMEs
21/11/2019